Nerve cell death inhibitor

Details Nerve cell death inhibitor Nerve cell death inhibitor

2011-07-05

2011-07-05

Kim, Jennifer M (Department: 1628)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

Reexamination Certificate

active

07973053

ABSTRACT:
The present invention provides a medicament exhibiting an excellent nerve cell death inhibitory action.The present invention relates to a nerve cell death inhibitor comprising a pitavastatin and donepezil or a salt thereof in combination.

REFERENCES:
patent: 6080778 (2000-06-01), Yankner et al.
patent: 6440387 (2002-08-01), Yankner et al.
patent: 6472421 (2002-10-01), Wolozin
patent: 2005/0215620 (2005-09-01), Friedhoff
patent: 2007/0110715 (2007-05-01), Grimaldi
patent: 2002-529500 (2002-09-01), None
patent: 99/48488 (1999-09-01), None
patent: 00/28981 (2000-05-01), None
patent: 01/32161 (2001-05-01), None
patent: 01/96311 (2001-12-01), None
patent: 02/062824 (2002-08-01), None
patent: 03/082298 (2003-10-01), None
patent: 2005/063294 (2005-07-01), None
patent: 2005/099823 (2005-10-01), None
patent: 2007/088705 (2007-08-01), None
T. Miida et al, “Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects”, Parmacol Ther, 2007, vol. 113, No. 2, pp. 378-393.
C. Oki et al, “Anti-Oxidative Effect of Pitavastatin against Ischemic Brain Damage”, Therapeutic Research, 2005, vol. 26, No. 6 pp. 1277-1286.
B. Wolozin et al, “Decreased Prevalence of Alzheimer Disease Associated with 3-Hydroxy-3-Methyglutaryl Coenzyme A Reductase Inhibitors,” Arch Neurol, Oct. 2000, vol. 57, pp. 1439-1443.
S. Akasofu et al, “Protective Effect of Donepezil in a Primary Culture of Rat Cortical Neurons Exposed to Oxygen-Glucose Deprivation,” European Journal of Pharmacology, 2003, No. 472, pp. 57-63.
J.T. Coyle et al, “Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation” Science, Mar. 11, 1983, vol. 219, pp. 1184-1190.
P. Doerfler et al, “Presenilin-dependent Gamma-Secretase Activity Modules Thymocyte Development,” PNAS, Jul. 31, 2001, vol. 98, No. 16, pp. 9312-9317.
J.A. Hardy et al, “Alzheirmer's Disease: The Amyloid Cascade Hypothesis,” Science, Apr. 10, 1992, vol. 256, pp. 184-185.
T. Hayashi et al, “HMG CoA Reductase Inhibitors Reduce Ischemic Brain Injury of Wistar Rats Through Decreasing Oxidative Stress on Neurons,” Brain Research, 2005, No. 1037, pp. 52-58.
A. Svensson et al, “Tacrine and Donepezil Attenuate the Neurotoxic Effect of ABeta(25-35) in Rat PC12 Cells,” NeuroReport, May 11, 1998, vol. 9, No. 7, pp. 1519-1522.
Y. Takada et al, “Nicotinic Acetylcholine Receptor-Mediated Neuroprotection by Donepezil Against Glutamate Neurotoxicity in Rat Cortical Neurons,” Journal of Pharmacology and Experimental Therapeutics, 2003, vol. 306, No. 2, pp. 772-777.
International Search Report of PCT/JP2008/002768, mailing date of Nov. 11, 2008.
Notification of Transmittal of Translation of the International Preliminary Report on Patentability (Form PCT/IB/338) of International Application No. PCT/JP2008/002768 mailed May 14, 2010, with Forms PCT/IB/373 and PCT/ISA/237.
Supplementary European Search Report dated Dec. 17, 2010, issued in corresponding European Patent Application No. 08 83 6702.
Kumagai, R. et al.; “Pitavastatin, a 3-hydroxy-3-methyglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, reduces hippocampal damage after transient cerebral ischemia in gerbils”; Journal of Neural Transmission, vol. 111, No. 9, Sep. 2004, pp. 1103-1120, XP002614678.
Roman, G et al.; “Efficacy and safety of donepezil in vascular dementia: results from the largest double-blind trial in vascular dementia patients”; European Neuropsychopharmacology, vol. 16, No. Suppl. 4, Sep. 2006, pp. S481-S482, XP002614677, & 19th Congress of the European—Collage—of—Neuropsychopharmacology; Paris, France, Sep. 16-20, 2006.
Tounai, Hiroko et al.; “Immunohistochemical Study on Distribution of NF-[kappa] B and p53 in Gerbil Hippocampus after Transient Cerebral Ischemia: Effect of Pitavastatin”; Metabolic Brain Disease, Klumer Academic Publishers-Plenum Publishers, NE, vol. 22, No. 1, Jan. 17, 2007, pp. 89-104, XP019482818.

Affiliated with

Also associated with

Rating

Nerve cell death inhibitor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Nerve cell death inhibitor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nerve cell death inhibitor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2672392